GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » Pre-Tax Income

Xbrane Biopharma AB (STU:7XB) Pre-Tax Income : €-31.47 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xbrane Biopharma AB Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Xbrane Biopharma AB's pretax income for the three months ended in Mar. 2024 was €-8.58 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was €-31.47 Mil. Xbrane Biopharma AB's pretax margin was -688.68%.

During the past 11 years, Xbrane Biopharma AB's highest Pretax Margin was -11.61%. The lowest was -31331.50%. And the median was -1279.60%.


Xbrane Biopharma AB Pre-Tax Income Historical Data

The historical data trend for Xbrane Biopharma AB's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Pre-Tax Income Chart

Xbrane Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.94 -21.44 -17.84 -15.33 -28.79

Xbrane Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.16 -7.76 -6.84 -8.28 -8.58

Competitive Comparison of Xbrane Biopharma AB's Pre-Tax Income

For the Biotechnology subindustry, Xbrane Biopharma AB's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xbrane Biopharma AB's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Pre-Tax Income falls into.



Xbrane Biopharma AB Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Xbrane Biopharma AB's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-27.709+0+-1.654+0.215+0.36
=-28.79

Xbrane Biopharma AB's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-7.523+0+-1.058+0+0
=-8.58

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-31.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xbrane Biopharma AB  (STU:7XB) Pre-Tax Income Explanation

Xbrane Biopharma AB's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=-8.581/1.246
=-688.68%

During the past 11 years, Xbrane Biopharma AB's highest Pretax Margin was -11.61%. The lowest was -31331.50%. And the median was -1279.60%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xbrane Biopharma AB Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Xbrane Biopharma AB (STU:7XB) Business Description

Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (STU:7XB) Headlines

No Headlines